





# PHARMACEUTICAL 2023

Prelude Therapeutics Inc  
Rank 120 of 446



The relative strengths and weaknesses of Prelude Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Prelude Therapeutics Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 78% points. The greatest weakness of Prelude Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 33% points.

The company's Economic Capital Ratio, given in the ranking table, is 179%, being 136% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	204,380
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	21,702
Liabilities, Non-Current	3,361
Other Assets	11,212
Other Compr. Net Income	-981
Other Expenses	0
Other Liabilities	0
Other Net Income	8,102
Other Revenues	0
Property and Equipment	4,908
Research and Development	92,889
Selling, General and Administrative Expense	30,651

Output Variable	Value in 1000 USD
Assets	220,500
Liabilities	25,063
Expenses	123,540
Revenues	0
Stockholders Equity	195,437
Net Income	-115,438
Comprehensive Net Income	-115,928
Economic Capital Ratio	179%